Atezolizumab (Tecentriq®) for adjuvant treatment of NSCLC. HTA ID: 22036

Assessment Status Full HTA submission received from Applicant
HTA ID 22036
Drug Atezolizumab
Brand Tecentriq®
Indication As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC.
Assessment Process
Rapid review commissioned 18/05/2022
Rapid review completed 02/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 04/10/2022
Full submission received from Applicant 02/12/2022